Compare Recursion Pharmaceuticals Inc (RXRX) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Exxon Mobil Corporation — how do they compare? Recursion Pharmaceuticals Inc trades at $3.34 (market cap $1.78B), while Exxon Mobil Corporation trades at $159.26 (market cap $634.34B). The key difference: Exxon Mobil Corporation is far larger — about 356.4× Recursion Pharmaceuticals Inc's market cap, and Exxon Mobil Corporation pays a 2.69% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | XOM | |
|---|---|---|
Market Cap | $1.78B | $634.34B |
Sector | Health | Energy |
52-Week High | $6.79 | $171.52 |
52-Week Low | $2.84 | $106.13 |
Enterprise Value | $1.30B | $673.57B |
Dividend Yield | — | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
ExxonMobil (XOM) trades at $159.80, up 4.49% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q1 2026 but missing in Q2, while revenue and net income have trended lower since 2022. The company maintains robust cash flow from operations and a solid balance sheet with low debt levels, supporting consistent dividends.
Outlook remains positive due to high oil price forecasts and Permian Basin growth, but risks include declining profitability margins and geopolitical volatility. The stock offers value near the consensus price target of $163.71, with institutional sentiment leaning bullish amid energy sector tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
